3118-68-1

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Cyanobenzenesulfonamide is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs aimed at treating a range of diseases, highlighting its importance in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 3-Cyanobenzenesulfonamide serves as a crucial component in the creation of different agrochemicals. Its incorporation contributes to the effectiveness of these products in agricultural applications.
Used in Dye Manufacturing:
3-Cyanobenzenesulfonamide is also employed in the manufacturing of dyes. Its chemical properties make it a valuable asset in producing a variety of dyes used across multiple industries.
Used in Organic Synthesis:
As a valuable intermediate in organic synthesis, 3-Cyanobenzenesulfonamide is used for its potential to generate new chemical structures. This versatility positions it as a vital component in advancing scientific research and chemical innovation.

InChI:InChI=1/C7H6N2O2S/c8-5-6-2-1-3-7(4-6)12(9,10)11/h1-4H,(H2,9,10,11)

Upstream product

• 56542-67-7 3-cyanobenzene sulfonyl chloride 
• 2237-30-1 m-cyanoaniline 
• 636-76-0 3-sulfamoylbenzoic acid 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 143-33-9 sodium cyanide 

Downstream Products

• 628298-58-8 3-(aminomethyl)benzenesulfonamide 
• 857003-88-4 3,3'-azanediylbis(methylene)dibenzenesulfonamide 
• 128924-59-4 C₁₄H₁₀ClN₃O₃S 
• 636-76-0 3-sulfamoylbenzoic acid 
• 7664-41-7 ammonia 
• 916210-25-8 tert-butyl (3-sulfamoylbenzyl)carbamate 
• 1124321-53-4 3-aminomethyl-benzenesulfonamide trifluoroacetate 
• 499152-52-2 N-(3-cyanophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide 
• 90000-88-7 N'-hydroxy-3-sulfamoylbenzimidamide 

Relevant academic research and scientific papers

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS

The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

Method for catalytic synthesis of N-benzyl benzene sulfonamide compounds by boric acid/oxalic acid catalytic system under microwave radiation

The invention discloses a method for catalytic synthesis of N-benzyl benzene sulfonamide compounds by a boric acid/oxalic acid catalytic system under microwave radiation. The method includes: adoptingbenzyl alcohol and derivatives thereof and benzene sulfonamide derivatives as raw materials, adopting the boric acid/oxalic acid system as a catalyst, and adopting fluorobenzene as a solvent; performing reaction in a microwave reactor under certain temperature and power conditions, performing vacuum concentration after reaction for a period of time, and subjecting a product to column chromatographic purification to realize efficient catalytic preparation of the N-benzyl benzene sulfonamide compounds. Compared with the prior art, the method has advantages of evidently higher reaction speed than that of conventional heating, mild reaction conditions, simplicity in operation, high yield, safety, low cost and environmental friendliness.

N-acyl sulfamide FBPase inhibitor, preparation method thereof, drug composition and application

The invention discloses an N-acryl sulfamide FBPase inhibitor of a novel structure, and a preparation method thereof, a drug composition and an application, and particularly relates to an N-acryl sulfamide FBPase inhibitor shown in the formula I, a salt thereof for medicine, a preparation method, a composition comprising one or more compounds, an application of the compound in preparing the FBPase inhibitor or a drug for treating FBPase-related diseases, and an application in preparing a drug for preventing and/or treating diabetes. The formula is shown in the description.

IMIDAZOPYRAZINE COMPOUNDS

Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.

TRIAZOLE OXADIAZOLES DERIVATIVES

The invention relates to compounds of formula (I), wherein R1, R2, Ra, Rb, X have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Multicyclic bis-amide MMP inhibitors

The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.

DISSOCIATION OF SUBSTITUTED BENZENESULPHONAMIDES IN WATER, METHANOL AND ETHANOL

Thirteen monosubstituted arylsulphonamides (XC6H4SO2NH2) and two 3,4-disubstituted arylsulphonamides (X2C6H3SO2NH2) have been synthetized and their dissociation constants have been measured by potentiometric titration in water, methanol, and ethanol.The Hammett substitution dependences have been calculated for all the media, and changes in the reaction constants due to transition from water to alcohols are discussed in confrontation with analogous dependences of benzoic acids.The reaction constant ρ found in methanol is lower than that in water.The dissociation constants have been treated by the method of the principal components and by multiple linear regression.